SynthesisRheumatology international2020
Prevalence of ankylosing spondylitis in a Chinese population: a systematic review and meta-analysis.
Synthesis in Rheumatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07130331 (Efficacy and Influencing Factors Analysis of Secukinumab in Patients With Axial Spondyloarthritis in a Real-World Setting), which is not on this map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Influencing Factors Analysis of Secukinumab in Patients With Axial Spondyloarthritis in a Real-World Setting
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Adverse events of tumor necrosis factor alpha inhibitors for the treatment of ankylosing spondylitis: A meta-analysis of randomized, placebo-controlled trials.Frontiers in pharmacology · 2023Pooled it
- Serum RANKL levels in Chinese patients with ankylosing spondylitis: a meta-analysis.Journal of orthopaedic surgery and research · 2021Pooled it
- Short-Term Efficacy and Safety of Secukinumab for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of RCTs.Mediators of inflammation · 2020Pooled it
- Monitoring the safety of the adjuvanted human papillomavirus vaccine HPV-16/18-AS04 in association with pregnancy and potential immune-related diseases in China: A retrospective observational cohort study.Human vaccines & immunotherapeutics · 2026Observational
- Zhuangdu Quhan Mixture Alleviates Ankylosing Spondylitis in Mice by Inhibiting the Interleukin-17 Signaling.Biomedical chromatography : BMC · 2026Article
- Clinical phenotype, MRI inflammatory involvement, and treatment patterns in HLA-B27 positive and negative axial spondyloarthritis: a Saudi MRI-based cohort study.BMC rheumatology · 2026Article
- Characterization of immune features and discovery of potential biomarkers for ankylosing spondylitis using deep plasma proteomics.Journal of advanced research · 2026Article
- Short-form video platforms as a source of ankylosing spondylitis information: a cross-sectional content analysis.Frontiers in digital health · 2026Article
- Management of Cervical Spinal Fractures With Ankylosing Spondylitis by Single-Anterior Surgery: A Case Series Report and Literature Review.Orthopaedic surgery · 2025Review
- Mechanical growth factor inhibited syndesmophyte formation and the progression of osteoarthritis and ankylosing spondylitis-like symptoms in HLA-B27/Hu-β2m transgenic rats.Arthritis research & therapy · 2025Article
- Association between immunoglobulin G N-glycosylation, inflammatory factors, and ankylosing spondylitis: A case-control study.Clinical rheumatology · 2025Article
- The role and predictive value of Th17/Treg imbalance and inflammatory factors in sagittal imbalance after VCD for ankylosing spondylitis.Journal of medical biochemistry · 2025Article
- Global epidemiology of spondyloarthritis.Nature reviews. Rheumatology · 2025Review
- Long-Term Outcomes of Functional Cup Positioned Total Hip Arthroplasty in Asian Ankylosing Spondylitis Patients.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2025Article
- ROC analysis determines optimal cutoff and doubtable interval of the Bath ankylosing spondylitis metrology index in a multicenter case control study.Scientific reports · 2025Article
- Causal Inference and Shared Molecular Pathways in Crohn's Disease, Celiac Disease, and Ankylosing Spondylitis: Integrative Mendelian Randomization and Transcriptomic Analysis.International journal of molecular sciences · 2025Article
- Diagnostic efficacy of dual-energy CT virtual non-calcium technique in the diagnosis of bone marrow edema of sacroiliac joints in ankylosing spondylitis.Journal of orthopaedic surgery and research · 2025Article
- Aberrant DNA Methylation Profile of Dickkopf-1 in Ankylosing Spondylitis.Biochemical genetics · 2024Article
- Home Transcutaneous Electrical Stimulation Rehabilitation Program for Patients With Ankylosing Spondylitis: Crossover Trial.JMIR formative research · 2024Article
- Targeted therapies and conventional care for the treatment of ankylosing spondylitis in China: a cost-effectiveness analysis based on the network-meta analysis.Journal of orthopaedic surgery and research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Ankylosing spondylitis (AS) is a common inflammatory rheumatic disease that affects the axial skeleton. In this study, we systematically reviewed Chinese AS epidemiological studies from the past 15 years to elucidate its prevalence and provide scientific data for China's health care system. AS epidemiological research in China was summarized by conducting a literature review. A review and statistical analysis of the literature on the epidemiology of AS in mainland China published from May 2005 to May 2019 were performed via a meta-analysis. We calculated the prevalence of AS and analysed differences by sex, region, and population source using STATA12.0 software. Eleven papers including 122,558 subjects from mainland China were included. Over the past 15 years, the total prevalence of AS in mainland China was 0.29% (95% CI 0.22-0.35%), ranging from 0.42% (95% CI 0.31-0.52%) in males to 0.15% (95% CI 0.13-0.18%) in females; the difference in the prevalence of AS by sex was statistically significant (P < 0.001). The prevalence of AS in both southern and northern China was 0.31% (95% CI 0.21-0.42% and 0.21-0.40%, respectively), with no significant difference noted (P = 0.816 > 0.005). The prevalence of AS in Chinese military populations was 0.27% (95% CI 0.09-0.45%), and in community populations, it was 0.29% (95% CI 0.23-0.35%). There was no statistically significant difference in the prevalence of AS by sampling resource (P = 0.115 > 0.005). The prevalence of AS in China was 0.29% and continues to increase. Sex differences in its prevalence were identified; the prevalence rate was 2.8 times higher in males than in females. Epidemiologists in China should formulate precise scientific investigations to provide additional authoritative epidemiological data for the prevention and treatment of AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.